Shares of Atyr Pharma Inc. (NASDAQ:LIFE) fell 2.5% on Thursday . The company traded as low as $2.71 and last traded at $2.74, with a volume of 184,785 shares. The stock had previously closed at $2.81.

A number of brokerages have recently weighed in on LIFE. William Blair cut shares of Atyr Pharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. BMO Capital Markets began coverage on shares of Atyr Pharma in a research note on Monday, April 11th. They issued a “market perform” rating for the company. Finally, Zacks Investment Research upgraded shares of Atyr Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $23.75.

The company’s market cap is $64.90 million. The stock has a 50-day moving average price of $3.04 and a 200 day moving average price of $4.64.

Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.02. On average, equities research analysts expect that Atyr Pharma Inc. will post ($2.79) EPS for the current fiscal year.

In other Atyr Pharma news, Director Paul Schimmel bought 66,219 shares of the stock in a transaction that occurred on Thursday, April 14th. The stock was acquired at an average cost of $4.18 per share, with a total value of $276,795.42. Following the purchase, the director now owns 53,012 shares in the company, valued at $221,590.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Grove Matsuoka bought 12,412 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $3.04 per share, with a total value of $37,732.48. Following the completion of the purchase, the insider now owns 2,412 shares in the company, valued at approximately $7,332.48. The disclosure for this purchase can be found here.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.